2,182 Johnson & Johnson $JNJ Shares Sold by Coastline Trust Co

Posted by George Bondi on Oct 1st, 2026

Coastline Trust Co lowered its stake in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 20.8% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 8,290 shares of the company’s stock after selling 2,182 shares during the quarter. Coastline Trust Co’s holdings in Johnson & Johnson were worth $2,195,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Outlook Capital Management LLC acquired a new stake in shares of Johnson & Johnson in the second quarter valued at about $28,000. Matrix Trust Co boosted its stake in Johnson & Johnson by 56.2% during the 2nd quarter. Matrix Trust Co now owns 150 shares of the company’s stock valued at $38,000 after purchasing an additional 54 shares during the period. Montgomery Financial Services LLC acquired a new stake in Johnson & Johnson in the 2nd quarter valued at approximately $43,000. Hyposwiss Advisors SA bought a new position in Johnson & Johnson in the 4th quarter worth approximately $42,000. Finally, Bullseye Investment Management LLC acquired a new position in shares of Johnson & Johnson during the second quarter worth approximately $63,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on JNJ shares. Citigroup raised their price objective on shares of Johnson & Johnson from $285.00 to $298.00 and gave the stock a “buy” rating in a research note on Wednesday, July 8th. UBS Group restated a “buy” rating on shares of Johnson & Johnson in a research report on Tuesday, September 22nd. Bank of America restated a “neutral” rating and set a $278.00 price objective on shares of Johnson & Johnson in a report on Tuesday. Wells Fargo & Company increased their target price on shares of Johnson & Johnson from $272.00 to $282.00 and gave the company an “overweight” rating in a research note on Monday, August 3rd. Finally, HSBC boosted their price target on Johnson & Johnson from $290.00 to $320.00 and gave the company a “buy” rating in a research note on Thursday, September 10th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat, Johnson & Johnson currently has an average rating of “Moderate Buy” and a consensus target price of $275.87.

Get Our Latest Stock Analysis on Johnson & Johnson

Insider Buying and Selling

In other Johnson & Johnson news, EVP Elizabeth Forminard sold 15,918 shares of Johnson & Johnson stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $257.00, for a total transaction of $4,090,926.00. Following the completion of the transaction, the executive vice president directly owned 16,994 shares of the company’s stock, valued at approximately $4,367,458. This trade represents a 48.37% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Timothy Schmid sold 33,597 shares of the company’s stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $274.74, for a total transaction of $9,230,439.78. Following the completion of the sale, the executive vice president directly owned 25,447 shares in the company, valued at approximately $6,991,308.78. The trade was a 56.90% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 87,569 shares of company stock valued at $23,064,544 in the last ninety days. Insiders own 0.16% of the company’s stock.

Key Stories Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

Positive Sentiment: Bank of America raised its price target for JNJ to $278 from $263, citing stronger expectations for Icotyde, Johnson & Johnson’s oral psoriasis treatment. The analyst now estimates the drug could generate up to $4.5 billion in peak sales, significantly above the prior $2.4 billion forecast. Icotyde sales estimate and price-target increase
Positive Sentiment: New IMAAVY data showed sustained disease control and reduced corticosteroid reliance among adolescents with generalized myasthenia gravis, with no new safety signals. The findings support the growth potential of J&J’s pharmaceutical pipeline. IMAAVY generalized myasthenia gravis data
Neutral Sentiment: JPMorgan reportedly expects JNJ’s stock to rise, while other coverage highlights the company’s strong economic moat, defensive business mix and long record of dividend increases. These factors may support the shares over the long term, but do not provide a major new near-term catalyst. JPMorgan analyst outlook
Neutral Sentiment: A global J&J survey found that most women do not associate eye-health changes with menopause. The announcement raises awareness of an eye-health issue but appears unlikely to materially affect near-term revenue or earnings. Global eye-health and menopause survey
Negative Sentiment: Investors are awaiting JNJ’s October 13 third-quarter earnings report, with one preview calling for roughly in-line revenue but an earnings miss. Another analyst report projected earnings about 12% below the consensus estimate, increasing caution ahead of the release. Johnson & Johnson third-quarter earnings preview
Negative Sentiment: JNJ has risen sharply over the past year and is trading near its record high, leaving less room for disappointment. Profit-taking and valuation concerns may be weighing on the shares while investors assess patent-cliff risks, including STELARA biosimilar erosion.

Johnson & Johnson Price Performance

NYSE:JNJ traded down $5.44 during mid-day trading on Thursday, hitting $259.30. The company’s stock had a trading volume of 2,178,303 shares, compared to its average volume of 7,947,242. The company has a market capitalization of $624.90 billion, a price-to-earnings ratio of 30.02, a P/E/G ratio of 2.55 and a beta of 0.24. The company has a current ratio of 1.09, a quick ratio of 0.81 and a debt-to-equity ratio of 0.44. Johnson & Johnson has a fifty-two week low of $182.94 and a fifty-two week high of $281.07. The stock has a fifty day moving average of $266.53 and a 200-day moving average of $248.19.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last released its quarterly earnings data on Wednesday, July 15th. The company reported $2.90 earnings per share for the quarter, beating analysts’ consensus estimates of $2.84 by $0.06. Johnson & Johnson had a return on equity of 32.42% and a net margin of 21.48%.The company had revenue of $25.31 billion for the quarter, compared to the consensus estimate of $25.06 billion. During the same period in the previous year, the business earned $2.77 earnings per share. The company’s quarterly revenue was up 6.6% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. As a group, equities analysts forecast that Johnson & Johnson will post 11.61 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 8th. Shareholders of record on Tuesday, August 25th were paid a dividend of $1.34 per share. This represents a $5.36 annualized dividend and a yield of 2.1%. The ex-dividend date was Tuesday, August 25th. Johnson & Johnson’s dividend payout ratio is currently 62.11%.

Johnson & Johnson Profile

(Free Report)

Johnson & Johnson (NYSE: JNJ) is a global healthcare company that develops, manufactures and markets products through two primary business segments: Innovative Medicine and MedTech. Its operations serve patients, healthcare professionals and consumers in markets around the world.

The Innovative Medicine segment focuses on prescription medicines in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.